Nonsymmetric P2/ P2′ Cyclic Urea HIV Protease Inhibitors
J ournal of Medicinal Chemistry, 1998, Vol. 41, No. 13 2423
gies for Intervention With HIV Infections. J . Med. Chem. 1995,
38, 2491-2517. (p) Boehme, R. E.; Borthwick, A. D.; Wyatt, P.
G. Antiviral Agents. Annu. Rep. Med. Chem. 1995, 30, 139-
149. (q) Chong, K. T. Recent Advances in HIV-1 Protease
Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (r) Kempf,
D. J .; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des.
1996, 2, 225-246. (s) De Lucca, G. V.; Erickson-Viitanen, S.;
Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of
Displacing the Active-Site Structural Water Molecule. Drug
Discovery Today 1997, 2, 6-18.
(8) Bryant, M.; Getman, D.; Smidt, M.; Marr, J .; Clare, M.; Dillard,
R.; Lansky, D.; DeCrecenzo, G.; Heintz, R.; Houseman, K.; Reed,
K.; Stoszenbach, J .; Talley, J .; Vazquez, M.; Mueller, R. SC-
52151, a novel inhibitor of the human immunodeficiency virus
protease. Antimicrob. Agents Chemother. 1995, 39, 2239-2234.
(9) (a) J adhav, P. K.; Ala, P.; Woerner, F. J .; Chang, C.-H.; Garber,
S. S.; Anton, E. D.; Bacheler, L. T. Cyclic Urea Amides: HIV-1
Protease Inhibitors with Low Nanomolar Potency against both
Wild Type and Protease Inhibitor Resistant Mutants of HIV. J .
Med. Chem. 1997, 40, 181-191. (b) For a schematic diagram of
the hydrogen bond interactions of the benzamides with HIVPR
based on the X-ray structure, see Figure 4 in ref 9a.
(10) Wilkerson, W. W.; Akamike, E.; Cheatham, W. W.; Hollis, A.
Y.; Collins, D.; DeLucca, I.; Lam, P. Y. S.; Ru, Y. HIV Protease
Inhibitory Bis-benzamide Cyclic Ureas: A Quantitative Structure-
Activity Relationship Analysis. J . Med. Chem. 1996, 39, 4299-
4312.
(11) (a) Rodgers, J . D.; J ohnson, B. L.; Wang, H.; Greenburg, R. A.;
Erickson-Viitanen, S.; Klabe, R. M.; Cordova, B. C.; Rayner, M.
M.; Lam, G. N.; Chang, C.-H. Potent Cyclic Urea HIV Protease
Inhibitors with Benzofused Heterocycles as P2/P2′ Groups.
Bioorg. Med. Chem. Lett. 1996, 6, 2919-2924. (b) Sun, J .-H.;
Teleha, C. A.; Yan, J .-S.; Rodgers, J . D.; Nugiel, D. A. Efficient
Synthesis of 5-(Bromomethyl) and 5-(Aminomethyl)-1-THF-
Indazole. J . Org. Chem. 1997, 62, 5627-5629.
(12) (a) De Lucca, G. V.; Liang, J .; Aldrich, P. E.; Calabrese, J .;
Cordova, B.; Klabe, R. M.; Rayner, M. M.; Chang, C.-H. Design,
Synthesis, and Evaluation of Tetrahydropyrimidinones As An
Example Of A General Approach to Non-peptide HIV Protease
(2) (a) Vella, S. HIV Therapy Advances. Update on a Proteinase
Inhibitor. AIDS 1994, 8 (Suppl 3), S25-29. (b) Pollard, R. B.
Use of Proteinase Inhibitors in Clinical Practice. Pharmaco-
therapy 1994, 14, 21S-29S. (c) Vacca, J . P.; Dorsey, B. D.;
Schlief, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay,
J .; Quintero, J . C.; Blahy, O. M.; Roth, E.; Sardana, V. V.;
Schlabach, A. J .; Graham, P. I.; Condra, J . H.; Gotlib, L.;
Holloway, M. K.; Lin, J .; Chen, I.-W.; Ostovic, D.; Anderson, P.
S.; Emini, E. A.; Huff, J . R. L-735,524: an Orally Bioavailable
Human Immunodeficiency Virus Type 1 Protease Inhibitor. Proc.
Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100. (d) Wei, X.; Ghosh,
S. K.; Taylor, M. E.; J ohnson, V. A.; Emini, E. A.; Deutsch, P.;
Lifson, J . D.; Bonhoeffer, S.; Nowak, M. A.; Hahn, B. H.; Saag,
M. S.; Shaw, G. M. Viral Dynamics in Human Immunodeficiency
Virus Type 1 Infection. Nature 1995, 373, 117-122. (e) Kempf,
D.; Marsh, K. C.; Denissen, J . F.; McDonald, E.; Vasavanonda,
S.; Flentge, C. A.; Green, B. G.; Fino, L.; Park, C. H.; Kong, X.-
P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham,
H. L.; Robins, T.; Stewart, K D.; Hsu, A.; Plattner, J . J .; Leonard,
J . M.; Norbeck, D. W. ABT-538 is a Potent Inhibitor of Human
Immunodeficiency Virus Protease with High Oral Bioavailability
in Humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
(f) Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.;
Leonard, J . M.; Markowitz, M. Rapid Turnover of Plasma Virons
and CD4 Lymphocytes in HIV-1 Infection. Nature 1995, 373,
123-126. (g) Kitchen, V. S.; Skinner, C.; Ariyoshi, K.; Lane, E.
A.; Duncan, I. B.; Burckhardt, J .; Burger, H. U.; Bragman, K.;
Pinching, A. J .; Weber, J . N. Safety and Activity of Saquinavir
in HIV Infection. Lancet 1995, 345, 952-955.
Inhibitors. J . Med. Chem. 1997, 40, 1707-1719. (b) For
a
schematic diagram of the hydrogen bond interactions of the
amidoxime with HIVPR based on the X-ray structure, see Figure
8 in ref 12a.
(13) Erickson-Viitanen, S.; Klabe, R. M.; Cawood, P. G.; O’Neal, P.
L.; Meek, J . L. Potency and Selectivity of Inhibitor of Human
Immunodeficiency Virus Protease by a Small Nonpeptide Cyclic
Urea, DMP323. Antimicrob. Agents Chemother. 1994, 38, 1628-
1634.
(14) Bacheler, L. T.; Paul, M.; J adhav, P. K.; Otto, M.; Stone, B.;
Miller, J . A. An assay for HIV RNA in Infected Cell Lysates,
and Its Use for the Rapid Evaluation of Antiviral Efficacy.
Antiviral Chem. Chemother. 1994, 5, 111-121.
(15) Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Erickson-Viitanen,
S.; Grubb, M. F.; Quon, C. Y.; Huang, S.-M. A Pharmacokinetic
Evaluation of HIV Protease Inhibitors, Cyclic Ureas, in Rats and
Dogs. Biopharm. Drug Dispos. 1994, 15, 535-544.
(3) (a) J acobsen, H.; Yasargil, K.; Winslow, D. L.; Craig, J . C.; Krohn,
A.; Duncan, I. B.; Mous, J . Characterization of Human Immu-
nodeficiency Virus Type 1 Mutants with Decreased Sensitivity
to Proteinase Inhibitor Ro 31-8959. Virology 1995, 206, 527-
534. (b) Markowitz, M. M.; Mo, H.; Kempf, D. J .; Norbeck, D.
W.; Bhat, T. N.; Erickson, J . W.; Ho, D. Selection and Analysis
of Human Immunodeficiency Virus Type
1 Variants with
Increased Resistance to ABT-538, a Novel Protease Inhibitor.
J . Virol. 1995, 69, 701-706. (c) Condra, J . H.; Schlelf, W. A.;
Blahy, O. M.; Gabryelski, L. J .; Graham, D. J .; Quintero, J . C.;
Rhodes, A.; Robbins, H. L.; Roth, E.; Shivaprakash, M.; Titus,
D.; Yang, T.; Teppler, H.; Squires, K. E.; Deutsch, P. J .; Emini,
E. A. In Vivo Emergence of HIV-1 Variants Resistant to Multiple
Protease Inhibitors. Nature 1995, 374, 569-571. (d) Ridky, T.;
Leis, J . Development of Drug Resistance to HIV-1 Protease
Inhibitors. J . Biol. Chem. 1995, 270, 29621-29623.
(16) Pierce, M. E.; Harris, G. D.; Islam, Q.; Radesca, L. A.; Storace,
L.; Waltermire, R. E.; Wat, E.; J adhav, P. K.; Emmett, G. C.
Stereoselective Synthesis of HIV-1 Protease Inhibitor, DMP 323.
J . Org. Chem. 1996, 61, 444-450.
(17) Rodgers, J . D.; Sun, J . H. Method for preparing HIV-protease-
inhibiting N-monosubstituted and N,N′-disubstituted unsym-
metrical cyclic ureas via alkylation and dealkylation of inter-
mediate isoureas. US 5,532,357, 1996.
(18) Katritzky, A. R.; Pilarski, B.; Urogdi, L. Efficient Conversion of
Nitriles to Amides with Basic Hydrogen Peroxide in Dimethyl
Sulfoxide. Synthesis 1989, 949-950.
(19) Nahm, S.; Weinreb, S. M. N-Methoxy-N-Methylamides as Ef-
fective Acylating Agents. Tetrahedron Lett. 1981, 22, 3815-3818.
(20) Einhorn, J .; Einhorn, C.; Luche, J .-L. A convenient method for
the Preparation of N-Methoxyamides. Synth. Commun. 1990,
20, 1105-1112.
(4) Lam, P. Y. S.; J adhav, P. K.; Eyermann, C. J .; Hodge, C. N.;
Ru, Y.; Bacheler, L. T.; Meek, J . L.; Otto, M. J .; Rayner, M. M.;
Wong, N. Y.; Chang, C. H.; Weber, P. C.; J ackson, D. A.; Sharpe,
T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavail-
able, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors.
Science 1994, 263, 380-384.
(5) Lam, P. Y. S.; Ru, Y.; J adhav, P. K.; Aldrich, P. E.; De Lucca, G.
V.; Eyermann, C. J .; Chang, C.-H.; Emmett, G.; Holler, E. R.;
Daneker, W. F.; Li, L.; Confalone, P. N.; McHugh, R. J .; Han,
Q.; Markwalder, J . A.; Seitz, S. P.; Bacheler, L. T.; Rayner, M.
M.; Klabe, R. M.; Shum, L.; Winslow, D. L.; Kornhauser, D. M.;
J ackson, D. A.; Erickson-Viitanen, S.; Sharpe, T. R.; Hodge, C.
N. Cyclic HIV Protease Inhibitors: Synthesis, Conformational
Analysis, P2/P2′ Structure-Activity Relationship, and Molecular
Recognition of Cyclic Ureas. J . Med. Chem. 1996, 39, 3514-3525.
(6) Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C.-H.;
Eyermann, C. J .; Garber, S.; Grubb, M.; J ackson, D. A.; J adhav,
P. K.; Korant, B.; Lam, P. Y. S.; Maurin, M. B.; Meek, J . L.;
Otto, M. J .; Rayner, M. M.; Reid, C.; Sharpe, T. R.; Shum, L.;
Winslow, D. L.; Erickson-Viitanen, S. Improved Cyclic Urea
Inhibitors of the HIV-1 Protease: Synthesis, Potency, Resistance
Profile, Human Pharmacokinetics and X-ray Crystal Structure
of DMP450. Chem. Biol. 1996, 3, 301-314.
(21) Winslow, D.; Horlick, R. A.; Anton, E. A.; Tritch, R. J .; Zagursky,
R. J .; Bacheler, L. T. A novel method for construction of
infectious molecular clones of HIV-1 containing defined muta-
tions in the HIV protease gene. Biochem. Biophys. Res. Commun.
1994, 205, 1651-1657.
(22) Otto, M. J .; Reid, C.; Garber, S.; Lam, P. Y. S.; Scaranti, H.;
Bacheler, L. T.; Rayner, M. M.; Winslow, D. In vitro anti-human
immunodeficiency virus (HIV) activity of XM323, a novel HIV
protease inhibitor. Antimicrob. Chemother. 1993, 37, 2606-2611.
(23) King, R. W.; Garber, S.; Winslow, D. L.; Reid, C.; Bacheler, L.
T.; Anton, E.; Otto, M. J . Multiple mutations in the human
immunodeficiency virus protease gene are responsible for de-
creased susceptability to HIV protease inhibitors. Antiviral
Chem. Chemother. 1995, 6, 80-88.
(24) Lin, Y.-i.; Lang, S. A., J r.; Lovell, M. F.; Perkins, N. A. New
Synthesis of 1,2,4-Triazoles and 1,2,4-Oxadiazoles. J . Org. Chem.
1979, 44, 4160-4164.
(7) Christ, D. D.; Meek, J . L.; Farmer, A. R.; Larsen, B. S. Oxidative
metabolism of the novel HIV protease inhibitor DMP 323 by rat,
dog and human systems. ISSX Proceedings 1993, 4, 230.
J M980103G